- Home
- BLTE vs IMCR Comparison
BLTE vs IMCR Comparison
Compare BLTE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- IMCR
- Stock Information
- Founded
- BLTE 2018
- IMCR 2008
- Country
- BLTE United States
- IMCR United Kingdom
- Employees
- BLTE N/A
- IMCR N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLTE Health Care
- IMCR Health Care
- Exchange
- BLTE Nasdaq
- IMCR Nasdaq
- Market Cap
- BLTE 2.1B
- IMCR 1.8B
- IPO Year
- BLTE 2022
- IMCR 2021
- Fundamental
- Price
- BLTE $68.01
- IMCR $33.41
- Analyst Decision
- BLTE Strong Buy
- IMCR Buy
- Analyst Count
- BLTE 4
- IMCR 10
- Target Price
- BLTE $96.67
- IMCR $58.13
- AVG Volume (30 Days)
- BLTE 45.0K
- IMCR 315.0K
- Earning Date
- BLTE 08-11-2025
- IMCR 08-07-2025
- Dividend Yield
- BLTE N/A
- IMCR N/A
- EPS Growth
- BLTE N/A
- IMCR N/A
- EPS
- BLTE N/A
- IMCR N/A
- Revenue
- BLTE N/A
- IMCR $356,145,000.00
- Revenue This Year
- BLTE N/A
- IMCR $27.43
- Revenue Next Year
- BLTE N/A
- IMCR $8.64
- P/E Ratio
- BLTE N/A
- IMCR N/A
- Revenue Growth
- BLTE N/A
- IMCR 26.78
- 52 Week Low
- BLTE $43.70
- IMCR $23.15
- 52 Week High
- BLTE $86.53
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- BLTE 59.16
- IMCR 43.90
- Support Level
- BLTE $68.99
- IMCR $31.02
- Resistance Level
- BLTE $74.49
- IMCR $33.73
- Average True Range (ATR)
- BLTE 3.27
- IMCR 1.62
- MACD
- BLTE 0.48
- IMCR -0.14
- Stochastic Oscillator
- BLTE 61.59
- IMCR 30.81
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.